Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Magnetar Financial LLC

Key Points

• Magnetar Financial LLC increased its stake in Arrowhead Pharmaceuticals by 389.8% during the first quarter, acquiring an additional 56,008 shares to reach a total ownership of approximately 0.05% of the company.
• Wall Street analysts have mixed ratings on Arrowhead Pharmaceuticals, with a consensus target price of $43.14 and two analysts giving a "Strong Buy" rating.
• Arrowhead Pharmaceuticals recently reported a quarterly loss of ($1.26) EPS, missing analysts' expectations, while revenues were also below estimates at $27.77 million.

Magnetar Financial LLC lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 389.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,375 shares of the biotechnology company's stock after purchasing an additional 56,008 shares during the quarter. Magnetar Financial LLC owned 0.05% of Arrowhead Pharmaceuticals worth $897,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $49,000. CWM LLC grew its stake in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $137,000. Finally, KBC Group NV grew its stake in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 2,132 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ARWR shares. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Royal Bank Of Canada dropped their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $43.14.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 9,389 shares of the business's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $20.00, for a total value of $187,780.00. Following the sale, the insider directly owned 262,122 shares in the company, valued at approximately $5,242,440. The trade was a 3.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Trading Up 8.3%

Shares of NASDAQ ARWR traded up $2.12 during trading on Wednesday, hitting $27.80. 5,336,292 shares of the company were exchanged, compared to its average volume of 2,012,189. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $27.86. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The company has a fifty day moving average price of $18.03 and a 200-day moving average price of $16.06. The firm has a market capitalization of $3.84 billion, a PE ratio of -21.72 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the previous year, the company posted ($1.38) EPS. As a group, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.